Cannabis Use, Neurobiology, Psychology, and Treatment offers readers a comprehensive reference on neurological changes, both transient and long-term, and other factors surrounding the use of these compounds and extracts. With coverage of both natural and synthetic cannabinoids, this broad coverage allows readers to learn about both adverse and non-adverse effects, including reactivity to pain, changes in behavior, and neuroactivity. This volume provides a platform for research on the effects of these compounds in brain function and neurological dysfunction. Extracts from the Cannabis sativa plant contain scores of psychoactive compounds in addition to the principal agent tetrahydrocannabinol, many of which are neuroactive.
1. Cannabis Use, Neurobiology, Psychology, and Treatment - p. Page i 2. Cover - p. Page i 3. Front Matter - p. Page i 4. Table of Contents - p. Page iv 5. Copyright - p. Page v 6. Dedication - p. Page vi 7. Contributors - p. Page vi 8. Preface - p. Page xi 9. List of Illustrations - p. Page xii 10. List of Tables - p. Page xiii 11. Chapter 1 : Metabolomics of the cannabis plant - p. Page xiii 12. Chapter 2 : Cannabis sativa roots: Chemical and pharmacological profile - p. Page 13 13. Chapter 3 : Cannabis-related compounds in beverages and food - p. Page 30 14. Chapter 4 : The impact of prenatal cannabis exposure: An overview - p. Page 52 15. Chapter 5 : Cannabinoid genotoxicity and congenital anomalies: A convergent synthesis of European and USA data sets - p. Page 63 16. Chapter 6 : Cannabis genotoxicity and cancer incidence: Highly concordant synthesis of European and USA datasets - p. Page 86 17. Chapter 7 : Cannabis, cognitive impairment and car crash risk - p. Page 107 18. Chapter 8 : Recreational cannabis use: French perspective of adverse effects - p. Page 121 19. Chapter 9 : Acute and chronic impact of cannabis on human cognition - p. Page 135 20. Chapter 10 : Polydrug users, use of cannabinoids and abuse potential: A focus on cannabidiol (CBD) - p. Page 150 21. Chapter 11 : Cannabis stigmas: A narrative of features - p. Page 166 22. Chapter 12 : Alterations of THC and CBD ratios and impact on cognition - p. Page 176 23. Chapter 13 : When cannabis is used for medicinal purposes: A focus on back pain - p. Page 187 24. Chapter 14 : Cannabis, cannabinoids, and receptor responses - p. Page 204 25. Chapter 15 : Cannabidiol (CBD): Abuse and physical dependence potential - p. Page 219 26. Chapter 16 : 4,5-Dihydro-1H-pyrazole/3,4-Diarylpyrazoline class of cannabinoid-1 (CB1R) receptor antagonists and their potential in medicinal applications - p. Page 235 27. Chapter 17 : Neurobiology of the endocannabinoid system and relevance to cannabis use - p. Page 245 28. Chapter 18 : Neurobiology of the kynurenine pathway and cannabis misuse: A new narrative - p. Page 260 29. Chapter 19 : Central nervous system cancers and use of cannabis and related products: An updated narrative - p. Page 275 30. Chapter 20 : The relationship between glutamate and resting-state connectivity in chronic cannabis users - p. Page 287 31. Chapter 21 : Brain metabolic responses to cannabis use in people with multiple sclerosis: Insights from [18F]-FDG positron emission tomography and functional MRI - p. Page 297 32. Chapter 22 : Genetic variation and acute responses to cannabis - p. Page 308 33. Chapter 23 : Cell signaling of the CB1 cannabinoid receptor via β-arrestins, cannabinoid receptor interacting protein (CRIP1a) and other regulatory proteins - p. Page 324 34. Chapter 24 : Impact of cannabis on memory: From in utero to adulthood - p. Page 336 35. Chapter 25 : Age-related considerations in the use of cannabinoids: Focus on drug interactions, physiology, and drug effects - p. Page 350 36. Chapter 26 : Cannabis, binge drinking, and memory in adolescents and young adults - p. Page 359 37. Chapter 27 : The role of ΔFosB in the plasticity of the cannabinoid system - p. Page 371 38. Chapter 28 : Functional profile of synthetic cannabinoid receptor agonists: Exploring cannabinoid and noncannabinoid targets - p. Page 371 39. Chapter 29 : Linking the G-protein-coupled receptor 55 (GPR55) to the cannabinoid receptors (CB1 and CB2): A new narrative - p. Page 390 40. Chapter 30 : Proteomic analysis of cannabinoids in human oligodendrocyte cells - p. Page 402 41. Chapter 31 : Cannabinoids and endocannabinoid signaling at the basal forebrain cholinergic system - p. Page 410 42. Chapter 32 : Cannabidiol (the major nonpsychotropic cannabinoid in the cannabis plant) and the PI3K/AKT signaling pathway in the CNS - p. Page 426 43. Chapter 33 : Effects of cannabidiol and other phytocannabinoids on voltage- and ligand-gated ion channels - p. Page 438 44. Chapter 34 : Cannabis, neurodevelopment, and the “two-hit” hypothesis - p. Page 450 45. Chapter 35 : Impact of Δ9-tetrahydrocannabinol (THC) and synthetic “spice” cannabinoids on nicotine use and abuse - p. Page 466 46. Chapter 36 : Synthetic cannabinoid receptor agonists compared to Δ9-tetrahydrocannabinol: Neurological effects and beyond - p. Page 481 47. Chapter 37 : The DSM: 5 Criteria of cannabis use disorder: Methods and applications - p. Page 491 48. Chapter 38 : Cannabis and clinical high risk for psychosis: Monitoring and smartphones - p. Page 507 49. Chapter 39 : The impact of cannabis and cannabinoids on the skin - p. Page 518 50. Chapter 40 : Cannabis consumption in reproductive function and teratogenicity - p. Page 532 51. Chapter 41 : Phytocannabinoids have cytotoxic, antiproliferative, and antimigratory activities on cancer cells and cancer stem cells - p. Page 549 52. Chapter 42 : Motivational interviewing for cannabis use disorders: A narrative review from research to practice - p. Page 561 53. Chapter 43 : An overview of current pharmacologic interventions for management of cannabis withdrawal syndrome and the evidence for their use - p. Page 576 54. Chapter 44 : Managing cannabinoid hyperemesis syndrome in pediatrics: A new narrative review - p. Page 588 55. Chapter 45 : Gabapentinoids for the treatment of cannabis use disorder: A focus on human laboratory research - p. Page 600 56. Chapter 46 : Treating psychosis in users of synthetic cannabinoids - p. Page 616 57. Chapter 47 : Recommended resources for studying and investigating cannabis use, neurobiology, psychology, and treatments - p. Page 624 58. Index - p. Page 634
Cannabis Use, Neurobiology, Psychology, and Treatment offers readers a comprehensive reference on neurological changes, both transient and long-term, and other factors surrounding the use of these compounds and extracts. With coverage of both natural and synthetic cannabinoids, this broad coverage allows readers to learn about both adverse and non-adverse effects, including reactivity to pain, changes in behavior, and neuroactivity. This volume provides a platform for research on the effects of these compounds in brain function and neurological dysfunction. Extracts from the Cannabis sativa plant contain scores of psychoactive compounds in addition to the principal agent tetrahydrocannabinol, many of which are neuroactive.
1. Cannabis Use, Neurobiology, Psychology, and Treatment - p. Page i 2. Cover - p. Page i 3. Front Matter - p. Page i 4. Table of Contents - p. Page iv 5. Copyright - p. Page v 6. Dedication - p. Page vi 7. Contributors - p. Page vi 8. Preface - p. Page xi 9. List of Illustrations - p. Page xii 10. List of Tables - p. Page xiii 11. Chapter 1 : Metabolomics of the cannabis plant - p. Page xiii 12. Chapter 2 : Cannabis sativa roots: Chemical and pharmacological profile - p. Page 13 13. Chapter 3 : Cannabis-related compounds in beverages and food - p. Page 30 14. Chapter 4 : The impact of prenatal cannabis exposure: An overview - p. Page 52 15. Chapter 5 : Cannabinoid genotoxicity and congenital anomalies: A convergent synthesis of European and USA data sets - p. Page 63 16. Chapter 6 : Cannabis genotoxicity and cancer incidence: Highly concordant synthesis of European and USA datasets - p. Page 86 17. Chapter 7 : Cannabis, cognitive impairment and car crash risk - p. Page 107 18. Chapter 8 : Recreational cannabis use: French perspective of adverse effects - p. Page 121 19. Chapter 9 : Acute and chronic impact of cannabis on human cognition - p. Page 135 20. Chapter 10 : Polydrug users, use of cannabinoids and abuse potential: A focus on cannabidiol (CBD) - p. Page 150 21. Chapter 11 : Cannabis stigmas: A narrative of features - p. Page 166 22. Chapter 12 : Alterations of THC and CBD ratios and impact on cognition - p. Page 176 23. Chapter 13 : When cannabis is used for medicinal purposes: A focus on back pain - p. Page 187 24. Chapter 14 : Cannabis, cannabinoids, and receptor responses - p. Page 204 25. Chapter 15 : Cannabidiol (CBD): Abuse and physical dependence potential - p. Page 219 26. Chapter 16 : 4,5-Dihydro-1H-pyrazole/3,4-Diarylpyrazoline class of cannabinoid-1 (CB1R) receptor antagonists and their potential in medicinal applications - p. Page 235 27. Chapter 17 : Neurobiology of the endocannabinoid system and relevance to cannabis use - p. Page 245 28. Chapter 18 : Neurobiology of the kynurenine pathway and cannabis misuse: A new narrative - p. Page 260 29. Chapter 19 : Central nervous system cancers and use of cannabis and related products: An updated narrative - p. Page 275 30. Chapter 20 : The relationship between glutamate and resting-state connectivity in chronic cannabis users - p. Page 287 31. Chapter 21 : Brain metabolic responses to cannabis use in people with multiple sclerosis: Insights from [18F]-FDG positron emission tomography and functional MRI - p. Page 297 32. Chapter 22 : Genetic variation and acute responses to cannabis - p. Page 308 33. Chapter 23 : Cell signaling of the CB1 cannabinoid receptor via β-arrestins, cannabinoid receptor interacting protein (CRIP1a) and other regulatory proteins - p. Page 324 34. Chapter 24 : Impact of cannabis on memory: From in utero to adulthood - p. Page 336 35. Chapter 25 : Age-related considerations in the use of cannabinoids: Focus on drug interactions, physiology, and drug effects - p. Page 350 36. Chapter 26 : Cannabis, binge drinking, and memory in adolescents and young adults - p. Page 359 37. Chapter 27 : The role of ΔFosB in the plasticity of the cannabinoid system - p. Page 371 38. Chapter 28 : Functional profile of synthetic cannabinoid receptor agonists: Exploring cannabinoid and noncannabinoid targets - p. Page 371 39. Chapter 29 : Linking the G-protein-coupled receptor 55 (GPR55) to the cannabinoid receptors (CB1 and CB2): A new narrative - p. Page 390 40. Chapter 30 : Proteomic analysis of cannabinoids in human oligodendrocyte cells - p. Page 402 41. Chapter 31 : Cannabinoids and endocannabinoid signaling at the basal forebrain cholinergic system - p. Page 410 42. Chapter 32 : Cannabidiol (the major nonpsychotropic cannabinoid in the cannabis plant) and the PI3K/AKT signaling pathway in the CNS - p. Page 426 43. Chapter 33 : Effects of cannabidiol and other phytocannabinoids on voltage- and ligand-gated ion channels - p. Page 438 44. Chapter 34 : Cannabis, neurodevelopment, and the “two-hit” hypothesis - p. Page 450 45. Chapter 35 : Impact of Δ9-tetrahydrocannabinol (THC) and synthetic “spice” cannabinoids on nicotine use and abuse - p. Page 466 46. Chapter 36 : Synthetic cannabinoid receptor agonists compared to Δ9-tetrahydrocannabinol: Neurological effects and beyond - p. Page 481 47. Chapter 37 : The DSM: 5 Criteria of cannabis use disorder: Methods and applications - p. Page 491 48. Chapter 38 : Cannabis and clinical high risk for psychosis: Monitoring and smartphones - p. Page 507 49. Chapter 39 : The impact of cannabis and cannabinoids on the skin - p. Page 518 50. Chapter 40 : Cannabis consumption in reproductive function and teratogenicity - p. Page 532 51. Chapter 41 : Phytocannabinoids have cytotoxic, antiproliferative, and antimigratory activities on cancer cells and cancer stem cells - p. Page 549 52. Chapter 42 : Motivational interviewing for cannabis use disorders: A narrative review from research to practice - p. Page 561 53. Chapter 43 : An overview of current pharmacologic interventions for management of cannabis withdrawal syndrome and the evidence for their use - p. Page 576 54. Chapter 44 : Managing cannabinoid hyperemesis syndrome in pediatrics: A new narrative review - p. Page 588 55. Chapter 45 : Gabapentinoids for the treatment of cannabis use disorder: A focus on human laboratory research - p. Page 600 56. Chapter 46 : Treating psychosis in users of synthetic cannabinoids - p. Page 616 57. Chapter 47 : Recommended resources for studying and investigating cannabis use, neurobiology, psychology, and treatments - p. Page 624 58. Index - p. Page 634
